GLUE Monte Rosa Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1826457 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-61.3%
TTM net income YoY-725.3%
TTM EPS YoY-574.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-214.5%
Net margin-186.2%
FCF margin-248.0%
EBITDA margin-202.8%
Returns
ROE-35.3%
ROA-22.6%
ROIC (approx.)-48.8%
Asset turnover0.12x
Leverage & solvency
Liabilities / assets28.9%
Debt / equity0.00x
Current ratio10.32x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.26x
Accruals ratio6.0%
Payout ratio—
Capex / revenue12.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $123.67M | $75.62M |
| R&D expense | $141.50M | $121.56M |
| SG&A expense | $36.38M | $35.17M |
| Operating income | -$54.21M | -$81.11M |
| Pretax income | -$39.72M | -$70.13M |
| Income tax | -$1.10M | $2.57M |
| Net income | -$38.63M | -$72.70M |
| EBITDA | -$45.85M | -$72.99M |
| EPS (diluted) | — | — |
| Weighted avg. shares (diluted) | 83.07M | 73.91M |
| Balance sheet | ||
| Cash & equivalents | $129.88M | $229.12M |
| Current assets | $393.19M | $377.44M |
| PP&E, net | $25.99M | $29.48M |
| Total assets | $448.66M | $438.73M |
| Current liabilities | $64.21M | $156.95M |
| Total liabilities | $215.60M | $215.80M |
| Shareholders' equity | $233.06M | $222.94M |
| Shares outstanding | 65.54M | 61.51M |
| Cash flow statement | ||
| Operating cash flow | -$22.80M | $42.00M |
| Capital expenditure | $4.70M | $3.99M |
| Free cash flow | -$27.50M | $38.01M |
| Investing cash flow | -$101.83M | -$44.45M |
| Financing cash flow | $30.35M | $98.89M |
| Depreciation & amortization | $8.36M | $8.12M |
| Stock-based compensation | $18.86M | $18.13M |
| Dividends paid | $0 | $0 |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.